目的 探讨血小板与淋巴细胞比值 (PLR) 在表皮生长因子受体 (EGFR) 突变型非小细胞肺癌 (NSCLC) 靶向治疗疗效与预后评价中的价值.方法 选取EGFR突变型NSCLC患者90例, 于靶向治疗前计算PLR, 以其中位数为截点分组, 分为A组 (低PLR组) 和B组 (高PLR组) .患者均予以EGFR-TKIs治疗.分析PLR与NSCLC临床病理特征的关系, 比较两组间客观疗效、ORR、DCR、PFS与OS的差异.结果 治疗前, PLR中位数为139, A组 (低PLR组, PLR≤139) 44例, B组 (高PLR组, PLR> 139) 46例.A组与B组在是否吸烟、肿瘤部位、组织分化、T分期、临床分期比较, 差异有统计学意义 (P <0.05) .A组PR、ORR、DCR率高于B组, PD率低于B组 (P <0.05) .A组中位OS、中位PFS均长于B组 (P=0.001) .结论 PLR在EG-FR突变型NSCLC靶向治疗疗效与预后评价中具有一定的参考价值, 低PLR的EGFR突变型NSCLC患者经靶向治疗后具有更高的疗效和更长的存活期, 是独立的预后评估因素.%Objective To explore the value of PLR in peripheral blood in the efficacy and prognosis of targeted therapy for NSCLC with EGFR-mutated. Methods Ninety patients with EGFR-mutant of NSCLC were selected, and the PLR was calculated before targeted therapy. The PLR median was used as a cut-off point for grouping, and they were assigned to group A (low PLR group) and group B (high PLR group). All patients were treated with EGFR-TKIs. Relationship between PLR and clinicopathological features was analyzed. Objective efficacy, ORR, DCR, PFS and OS between the two groups were compared. Results Before EGFR-TKIs therapy, median PLR was 139, and there were 44 patients in group A, and 46 in group B. There were statistical differences regarding smoking, tumor location, histological differentiation, T staging, and clinical staging between group A and B (P <0.05). The rates of PR, ORR and DCR in group A were higher than those in group B, and the PD rate was lower than that in group B (P < 0.05). Log-rank test showed that median OS and median PFS in group A were longer than those in group B (P= 0.001). Conclusions PLR in peripheral blood has certain reference value for therapeutic effect and prognosis evaluation on NSCLC with EGFR-mutation. Low PLR of NSCLC patients with EGFR-mutation has higher efficacy and longer survival time after targeted therapy, and it is an independent and prognostic factor.
展开▼
